DNLI
NASDAQ HealthcareDenali Therapeutics Inc. - Common Stock
Biotechnology
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
�� 市场数据
| 价格 | $20.57 |
|---|---|
| 成交量 | 1,438,783 |
| 市值 | 3.26B |
| 贝塔系数 | 1.100 |
| RSI（14日） | 64.9 |
| 200日均线 | $17.20 |
| 50日均线 | $20.25 |
| 52周最高 | $23.77 |
| 52周最低 | $12.31 |
| Forward P/E | -7.96 |
| Price / Book | 3.17 |
🎯 投资策略评分
DNLI 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (65/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (24/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 DNLI in your text
粘贴任何文章、记录或帖子 — 工具将提取 DNLI 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.